Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial, further expanding its injectable product portfolio in the United States. The product is both bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL), marketed by Provepharm SAS under NDA 204630. With this launch, Glenmark continues to strengthen its presence in the institutional and hospital-focused pharmaceutical segment.
Addressing a Growing Market Opportunity
The introduction of Methylene Blue Injection USP comes at a time when demand for critical injectable therapies remains strong. According to IQVIA® data, the U.S. market for ProvayBlue® Injection generated approximately $19 million in annual sales during the 12-month period ending April 2026. By bringing a cost-effective and high-quality alternative to the market, Glenmark aims to enhance treatment accessibility while supporting healthcare providers with reliable therapeutic options.
Strengthening Institutional Healthcare Offerings
Marc Kikuchi, President and Business Head, North America, emphasized Glenmark’s commitment to expanding patient access to essential medicines. “The launch of Methylene Blue Injection USP reflects Glenmark’s ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. This addition further strengthens our institutional portfolio and reinforces our focus on delivering reliable treatment options across the U.S. market,” said Kikuchi.
Expanding Glenmark’s Injectable Portfolio
The launch underscores Glenmark’s continued focus on broadening its injectable and institutional product offerings. Moreover, it aligns with the company’s strategy of delivering affordable, high-quality pharmaceutical products that address evolving healthcare needs across the United States. As per the press release, as Glenmark continues to invest in product development and portfolio expansion, the company remains focused on supporting healthcare systems with dependable medicines while improving patient access to critical therapies.
